Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corp (NY: GKOS )

85.56 USD +0.77 (+0.91%)
Streaming Delayed Price Updated: 10:58 AM EDT, Jun 23, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Glaukos Corp

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Gets Technical Rating Upgrade
Glaukos shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
From Investor's Business Daily
Greg Kunst Appointed CEO of Aurion Biotech
Aurion Biotech launches; Greg Kunst joins as CEO 
From Business Wire News Releases
Glaukos Announces Australia’s TGA Regulatory Approval for PRESERFLO™ MicroShunt
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Getting Closer To Key Technical Measure
A Relative Strength Rating upgrade for Glaukos shows improving technical performance. Will it continue? 
From Investor's Business Daily
Glaukos Corp (GKOS) Q1 2021 Earnings Call Transcript
GKOS earnings call for the period ending March 31, 2021. 
Tags Market News GKOS
From Motley Fool
Glaukos Corporation Announces First Quarter 2021 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags MTCR LOGC SGEN
From Benzinga
Glaukos's Earnings: A Preview
Glaukos (NYSE:GKOS) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's look at Glaukos's Q1 earnings ... 
Tags Earnings Benzinga BZI/EP
From Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA ... 
Tags NVTA ANIP GKOS
From Benzinga
Glaukos Announces the Release of its 2020 Sustainability Report
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags BSX LGVN UTHR
From Benzinga
Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to... 
From Business Wire News Releases
Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2021
Upgrades According to Oppenheimer, the prior rating for Glaukos Corp (NYSE:GKOS) was changed from Perform to Outperform. ... 
Tags Downgrades USB HOOK
From Benzinga
Why Glaukos's Stock is Up During Today's Session
Glaukos's Stock Price And Volume Action Glaukos (NYSE:GKOS) is currently up 4.05% to a price of $83.45. Thursday the stock has ... 
Tags Trading Ideas Market News GKOS
From Benzinga
Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening Initiatives
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags BSX MRVI AMPE
From Benzinga
The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags FDA MRK MORF
From Benzinga
Glaukos Announces Participation in Oppenheimer Healthcare Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Corp (GKOS) Q4 2020 Earnings Call Transcript
GKOS earnings call for the period ending December 31, 2020. 
Tags Market News GKOS
From Motley Fool
Glaukos' iLink Therapy Meets Primary Endpoint In Late-Stage Vision Disorder Study
Glaukos Corp(NYSE:GKOS) hasannounced topline datafrom the U.S. Phase 3 trial evaluating its corneal ... 
Tags General Benzinga Health Care
From Benzinga
The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags APYX DRNA BCAB
From Benzinga
Glaukos: Q4 Earnings Insights
Shares of Glaukos (NYSE:GKOS) were flat after-market trading after the company reported Q4 results. Quarterly Results Earnings per ... 
Tags Benzinga BZI/Recaps Earnings
From Benzinga
Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
Glaukos Announces Positive Phase 3 Trial Results for iLink™ Epi-on Investigational Therapy That Met the Primary Efficacy Endpoint
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today... 
From Business Wire News Releases
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags XENE ICLR GKOS
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback